This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: K51.0 (Ulcerative pancolitis) | Special Copayment Reduction: V131 (severe intractable disease, 5 years) |
| B. Synonyms | total ulcerative colitis, pancolitis ulcerative colitis, ulcerative pancolitis, pan-ulcerative colitis |
| C. Adult onset | Adult onset high — ulcerative colitis shows a bimodal onset distribution at ages 15–35 and 55–65, and pancolitis can present in children, adolescents, and adults alike. The proportion of pancolitis at diagnosis is about 20–30% in adults and higher in children. |
| 1. History | 1859 first description by Wilks → 1930s international recognition spreads → 1955 sulfasalazine introduced → 1980s mesalazine → 1990s opening of the anti-TNF biologic era |
| 2. Causes | Genetic predisposition + gut microbial abnormality + mucosal immune dysregulation + environmental factors (smoking, appendectomy, NSAIDs, diet) |
| 3. Genetics | HLA-DR2 association, unrelated to NOD2 (distinguishing it from Crohn disease), more than 200 susceptibility loci including IL-10, IL-23R, ECM1, and HNF4A |
| 4. General epidemiology | Western prevalence 100~200/100,000, rapid increase in Korea; pancolitis accounts for 20~30% of UC; phenotype with the highest colorectal cancer risk |
| 5. Pathophysiology | Mucosal barrier damage → exposure to microbial antigens → dendritic cell activation → Th2/Th9/Th17-mediated inflammation → neutrophil infiltration → mucosal ulcer |
| 6. Symptoms | Bloody diarrhea, mucoid stool, abdominal pain (mainly left lower abdomen), urgency, frequent bowel movements, fever, weight loss |
| 7. Signs | Abdominal tenderness, hyperactive bowel sounds, anemia findings, oral ulcers, erythema nodosum, uveitis, possible primary sclerosing cholangitis |
| 8. Screening | Fecal occult blood, fecal calprotectin, CBC, CRP, ESR; early endoscopic surveillance in high-risk groups (family history, PSC) |
| 9. Diagnosis | Colonoscopy + biopsy (gold standard); capsule endoscopy and MR enterography as adjuncts; exclusion of infectious colitis |
| 10. Treatment | Mild-to-moderate: oral + enema mesalazine; moderate-to-severe: corticosteroids, azathioprine; refractory: anti-TNF, vedolizumab, ustekinumab, JAK inhibitors; surgery: total proctocolectomy |
| 11. Prognosis | Pancolitis is the phenotype with the highest surgery rate and colorectal cancer risk; 10-year surgery rate about 20%; surveillance endoscopy for colorectal cancer is essential 8~10 years after diagnosis |
| 12. Prevention | Long-term mesalazine maintenance, colorectal cancer surveillance endoscopy, smoking correction not needed (non-smoking is a risk factor for UC), regular follow-up |
| 13. References | Ordás et al. Lancet 2012; Fumery et al. Clin Gastroenterol Hepatol 2017 and 8 others |
The history of ulcerative colitis (UC) began in 1859 when the English physician Samuel Wilks first described a case he observed at Guy's Hospital in London. Wilks named a patient with bloody diarrhea and inflammation and ulceration of the entire colon 'simple ulcerative colitis', and this term subsequently became established as the standard diagnostic name for ulcerative colitis. Pancolitis, the form involving the whole colon from the cecum to the rectum, is the most extensive phenotype of the disease, and it was recognized from the early days that its clinical course is severe and its complication risk high.
From the late 19th to the early 20th century, when colonoscopy technology did not exist, pancolitis was identified through surgical or autopsy findings. In the 1920s–30s, Burrill Crohn described Crohn disease, raising the need for differentiation from ulcerative colitis, and by the 1950s sigmoidoscopy and barium enema radiography were introduced for diagnosis. In 1955, sulfasalazine, developed by Nanna Svartz, was introduced for UC treatment, opening the era of the first drug treatment. Sulfasalazine is a conjugate of an antibacterial component (sulfapyridine) and an anti-inflammatory component (5-aminosalicylic acid, 5-ASA), which later led to the development of mesalazine (5-ASA alone) in the 1980s.
In the 1960s–70s, corticosteroids (ACTH and oral prednisolone) were confirmed to be effective for the acute phase of severe UC, and Truelove and Witts first demonstrated the efficacy of steroids in a randomized controlled trial in 1955. The Truelove-Witts criteria subsequently became the standard for classifying UC severity. In the 1990s, anti-TNF biologics such as infliximab were confirmed to be effective in steroid-refractory UC, and the era of biologics opened after US FDA approval in 2005. After the 2010s, treatments with new mechanisms were approved, such as vedolizumab (a gut-selective anti-α4β7 antibody), ustekinumab (an anti-IL-12/23 antibody), and JAK inhibitors (tofacitinib, upadacitinib), greatly expanding treatment options. In Korea, the incidence of UC has risen sharply since the 2000s and is approaching Western levels, and the proportion of pancolitis is also increasing.
The cause of ulcerative pancolitis is understood as a complex interaction of genetic predisposition, gut microbial abnormality (dysbiosis), mucosal immune dysregulation, and environmental factors. It is a multifactorial disease not explained by a single cause.
The concordance rate of UC in monozygotic twins is about 10~15%, lower than in Crohn disease (50% or more), indicating a greater relative weight of environmental factors. However, with a family history, the risk of onset increases about 10~15-fold. GWAS studies have identified more than 200 susceptibility loci, and the HLA region (particularly the HLA-DR2 allele) is the strongest genetic risk factor. Genes such as IL-10, IL-23R, ECM1, HNF4α, and LAMB1 are also associated with UC susceptibility.
In UC patients, dysbiosis is observed in which gut microbial diversity is reduced compared with healthy people, short-chain fatty acid-producing bacteria such as Faecalibacterium prausnitzii decrease, and Fusobacterium, Proteobacteria, and others increase. Changes in the gut flora act as continuous stimulation of mucosal immune activation. There are also reports that the degree of dysbiosis is more severe in patients with pancolitis.
In UC, abnormal epithelial barrier function of the intestinal mucosa (reduced expression of tight junction proteins) allows luminal antigens to invade the lamina propria and triggers an abnormal immune response by dendritic cells and macrophages. Th2 and Th9 immune responses play the main role, and IL-5 and IL-13 promote epithelial damage and eosinophil infiltration. Reduced regulatory T cell (Treg) function is also involved.
Smoking paradoxically has a protective effect in UC (the opposite of Crohn disease), and cases of UC onset or worsening after smoking cessation have been reported. A history of appendectomy is known to lower the incidence of UC. NSAIDs, antibiotics (disruption of gut microbiota), oral contraceptives, a high-fat low-fiber diet, urbanization and improved hygiene (hygiene hypothesis), and stress are being studied as risk factors.
The genetic basis of ulcerative colitis is being rapidly elucidated through genome-wide association study (GWAS) research. More than 200 susceptibility loci have been identified so far, of which about 30% are commonly associated with both UC and Crohn disease and the rest are specific to UC.
HLA region: The HLA (human leukocyte antigen) region on the short arm of chromosome 6 is the genomic region showing the strongest association with IBD susceptibility. In UC, the risk of onset is markedly increased in carriers of HLA-DR2 (DRB1*01502 allele), with HLA-DQ also involved. In contrast, the NOD2 variants important in Crohn disease are not associated with increased risk of onset in UC, which is used to genetically differentiate the two diseases.
IL-10 pathway: Variants of the genes for the anti-inflammatory cytokine IL-10 and its receptors (IL-10RA, IL-10RB) are associated with severe early-onset UC. Reduced IL-10 signaling impairs a pathway essential for maintaining regulatory T cell function and promotes chronic intestinal inflammation. IL-10 receptor loss-of-function variants can cause very early onset IBD in infancy.
ECM1 gene: Polymorphisms of the ECM1 gene, which encodes extracellular matrix protein 1, are a UC-specific susceptibility locus and are involved in maintaining epithelial barrier function. ECM1 regulates mucosal permeability through interaction with tight junction proteins.
HNF4α: Single nucleotide polymorphisms (SNPs) of the hepatocyte nuclear factor 4α (HNF4A) gene are associated with increased UC risk. HNF4α is needed for differentiation of colonic epithelial cells and maintenance of tight junctions, and its deficiency increases mucosal permeability.
Other susceptibility genes: IL-23R (interleukin-23 receptor), IL-12B, STAT3, LAMB1 (laminin beta 1), CDH1 (E-cadherin), PTPN2, CARD9, and others are known to contribute to UC susceptibility. These genes are involved in diverse biological pathways, including intestinal epithelial barrier function, innate immune signaling, and adaptive immune regulation. Research on pancolitis-specific genetic susceptibility is ongoing, and associations between extent of disease and specific genotypes are being explored.
Ulcerative colitis shows a high prevalence in Westernized countries worldwide and is increasing rapidly in developing countries as well. In North America and Europe, the UC prevalence reaches 100~200 per 100,000 population, and the incidence is 10~20 per 100,000 per year. In Asian countries, the incidence has also increased severalfold over the past several decades.
Epidemiology in Korea: The incidence of UC in Korea has risen sharply since the 2000s, reaching 3~5 per 100,000 per year in the 2010s. In studies based on National Health Insurance Service data, UC prevalence rose from about 7.6/100,000 in 2005 to more than 30/100,000 in 2017. The median age at diagnosis is 30~35 years, with a bimodal distribution (ages 15~35 and 55~65).
Proportion of pancolitis: At the time of UC diagnosis, the extent of lesions is distributed as proctitis 30~40%, left-sided colitis 20~30%, and pancolitis 20~30%. Pancolitis accounts for a relatively high proportion in children and adolescents and about 20~30% in adults. In some patients, pancolitis can extend over time from previously limited lesions (disease extension), and 10 years after diagnosis about 20~30% of left-sided colitis patients progress to pancolitis.
Accompanying primary sclerosing cholangitis (PSC): PSC accompanies in about 2~4% of UC patients, and conversely UC (especially pancolitis) accompanies in about 70~80% of PSC patients. UC with PSC is associated with 'backwash ileitis' mainly involving the right colon, and has a still higher colorectal cancer risk.
Colorectal cancer risk: Pancolitis is the UC phenotype with the highest risk of colorectal cancer (CRC). The cumulative CRC risk is reported to be about 1~2% within 10 years of diagnosis, about 5~10% after 20 years, and about 15~20% after 30 years. The risk increases further in pancolitis with PSC.
The pathophysiology of ulcerative pancolitis is explained as a continuous process leading from mucosal barrier damage, exposure to gut microbial antigens, and abnormal activation of innate and adaptive immune responses to persistent inflammation. Pancolitis is the state in which this pathophysiology is expressed across the entire colon from the cecum to the rectum.
In the normal colonic mucosa, the epithelial layer, composed of enterocytes, goblet cells, enteroendocrine cells, and others, is tightly connected through tight junctions to block invasion of luminal antigens into the lamina propria. In UC, abnormal expression and redistribution of tight junction proteins such as claudin-1, claudin-2, occludin, and ZO-1 increase intestinal permeability. Reduced mucin secretion by goblet cells also contributes to decreased defense function. Whether this barrier damage precedes inflammation or is a result of it is debated, but the hypothesis that barrier damage acts as a trigger in genetically vulnerable individuals is favored.
Dendritic cells and macrophages in the intestinal lamina propria are activated by recognizing microbe-associated molecular patterns (MAMP: lipopolysaccharide, flagellin, etc.) exposed through increased intestinal permeability via pattern recognition receptors (TLR, NLR). As a result, proinflammatory cytokines such as IL-1β, IL-6, TNF-α, IL-12, and IL-23 are secreted, and neutrophils flood into the mucosa. Neutrophils are the key cells in forming cryptitis and crypt abscesses, and worsen epithelial damage by secreting reactive oxygen species (ROS) and proteolytic enzymes.
In UC, unlike Crohn disease, the adaptive immune response mainly shows a Th2 and Th9-skewed response. IL-13 (Th2-derived) suppresses expression of tight junction proteins in epithelial cells and inhibits goblet cell differentiation. IL-9 (Th9-derived) is also involved in increased intestinal permeability and mast cell activation. Evidence is accumulating that Th17 cells (IL-17A, IL-17F) also play a role in UC pathophysiology, but caution is needed because Th17-targeted treatment (anti-IL-17) can actually cause worsening in UC. Reduced regulatory T cell (Treg) function and decreased IL-10 production lead to failure of the anti-inflammatory pathway.
Mucosal ulcers form through persistent neutrophil and macrophage inflammatory responses and increased epithelial cell apoptosis. UC ulcers, unlike Crohn disease, are confined to the mucosa and submucosa (non-penetrating) and are characteristically continuously distributed. Chronic inflammation produces histological changes such as crypt architectural distortion, basal plasmacytosis, Paneth cell metaplasia, and muscularis mucosae thickening.
Ulcerative pancolitis involves the whole colon from the rectum to the cecum, so symptoms are more severe than in left-sided colitis or proctitis, and systemic symptoms often accompany.
Bloody diarrhea is the most characteristic symptom, with bright red blood mixed in loose stools 4~10 or more times a day. Mucoid stool is also common, accompanied by lower abdominal cramping pain and urgency before defecation. In pancolitis, inflammation of the entire colon severely reduces the colon's water and electrolyte absorption function, so dehydration and electrolyte imbalance (hypokalemia, hyponatremia) can occur. Unlike left-sided colitis, the right colon is also involved, causing tenderness and discomfort throughout the abdomen. Abdominal pain mainly worsens before defecation and is relieved after defecation, and persistent abdominal pain suggests severe disease activity or a complication (toxic megacolon).
In severe pancolitis, fever (38°C or above), tachycardia (>90 beats/min), weight loss, anorexia, and fatigue appear. Iron deficiency anemia due to chronic bleeding and malabsorption and anemia of chronic disease occur. In severe cases, edema due to hypoalbuminemia, growth retardation (children and adolescents), and osteoporosis may accompany.
Extraintestinal symptoms occur in about 25~40% of UC patients, with a higher frequency in pancolitis. Joint symptoms (peripheral arthralgia, spondyloarthropathy) are the most common, and may be related to colonic inflammatory activity (peripheral) or progress independently (axial). Skin symptoms are typified by erythema nodosum and pyoderma gangrenosum. Ocular symptoms such as uveitis and episcleritis may appear, and early detection is important because of the risk of visual impairment. Primary sclerosing cholangitis (PSC) shows a strong association with pancolitis and often progresses independently of colonic inflammation.
Disease activity and the presence of complications are assessed by integrating physical signs and laboratory findings.
In mild-to-moderate pancolitis, abdominal tenderness (mainly left and lower abdomen) and hyperactive bowel sounds are observed. In severe or fulminant disease, abdominal distension, rebound tenderness (with complications), and decreased bowel sounds (in toxic megacolon) may appear. Tachycardia, fever, and hypotension are systemic signs of severe disease. Bloody discharge may be found on digital rectal examination.
Blood tests show anemia (decreased Hb, microcytic or normocytic), inflammatory response (elevated CRP, increased ESR, leukocytosis), hypoalbuminemia, and thrombocytosis (reactive). Fecal calprotectin is a sensitive noninvasive marker of intestinal inflammation, markedly elevated (>150 μg/g) in active pancolitis, and used to monitor disease activity and treatment response. Stool tests show positive occult blood and leukocytosis. To exclude infectious colitis, stool culture and toxin testing (including Clostridioides difficile) are performed.
Colonoscopy is the reference test for UC diagnosis and activity assessment. In pancolitis, erythema, edema, loss of vascular pattern, granular mucosa, spontaneous bleeding, exudate, and ulcers are observed continuously from the cecum to the rectum. Activity is quantified with the Mayo endoscopic score or the UC Endoscopic Index of Severity (UCEIS). Mucosal healing is the current treatment goal, with a Mayo score of 0 or 1 as the standard.
UC screening of the general population is currently not recommended. However, early detection in specific high-risk groups and colorectal cancer surveillance endoscopy in patients already diagnosed with pancolitis have important clinical significance.
Fecal calprotectin is a highly sensitive noninvasive marker of intestinal mucosal inflammation and is useful for differentiating active IBD from functional bowel disease (irritable bowel syndrome, etc.). Calprotectin >150 μg/g suggests the possibility of organic bowel disease and prompts colonoscopy. Fecal occult blood testing is used for colorectal cancer screening and, together with the bloody diarrhea symptoms of UC, can be used as the first screening tool for organic bowel disease.
Because patients with pancolitis have a high risk of colorectal cancer, regular surveillance colonoscopy is recommended starting 8~10 years after diagnosis. The surveillance interval is differentiated by risk. Surveillance is recommended annually for the high-risk group (with PSC, history of dysplasia, family history), every 2~3 years for the intermediate-risk group (extensive inflammation, post-inflammatory polyps), and every 5 years for the low-risk group. Random and targeted biopsies using chromoendoscopy or high-definition white-light endoscopy are the recommended methods.
When PSC is diagnosed, the presence of accompanying UC (especially pancolitis) must be confirmed by colonoscopy. PSC-UC carries a still higher colorectal cancer risk, so annual surveillance colonoscopy is performed from immediately after PSC diagnosis. The colorectal cancer prevention effect of ursodeoxycholic acid is debated, but it is used for the purpose of protecting liver function.
Diagnosis of ulcerative pancolitis is made by integrating clinical symptoms, endoscopic findings, and histopathological findings, and it is essential to exclude other inflammatory bowel diseases, including infectious colitis and Crohn disease.
Colonoscopy is the gold standard for UC diagnosis. Total colonoscopy is performed at the first visit to confirm the extent of lesions. In pancolitis, continuous mucosal inflammation from the cecum to the rectum is confirmed, and the terminal ileum is also examined to assess backwash ileitis and to differentiate from Crohn disease. Biopsies are taken from at least 5 sites (cecum, ascending, transverse, and descending colon, rectum). On histopathology, crypt architectural distortion, basal plasmacytosis, full-thickness mucosal inflammation (distinguished from the transmural inflammation of Crohn disease), goblet cell depletion, and Paneth cell metaplasia are characteristic.
Acute infectious colitis (Salmonella, Shigella, Campylobacter, Clostridioides difficile, amebic colitis, etc.) shows symptoms similar to UC and is excluded by stool culture and toxin testing. Differentiation from Crohn disease is judged by integrating clinical (perianal lesions, small bowel involvement, fistula formation), endoscopic (skip lesions, cobblestone mucosa, deep fissuring ulcers), histological (transmural granulomatous inflammation), and radiological findings. When confirmation is difficult, it is classified as 'indeterminate colitis'. Ischemic colitis, radiation colitis, and collagenous colitis are also differential diagnoses.
CT or MR enterography is useful for evaluating small bowel involvement (differentiation from Crohn disease) and complications (stricture, fistula, abscess). Plain abdominal X-ray is used to screen for toxic megacolon in acute severe UC (transverse colon diameter >6 cm). Intestinal ultrasonography, a noninvasive method that assesses disease activity and extent without radiation exposure, is increasingly used.
Treatment of ulcerative pancolitis consists of two stages: induction of remission and maintenance of remission. The treatment goal goes beyond symptom relief to achieving mucosal healing and deep remission (clinical, endoscopic, and histological remission).
5-aminosalicylic acid (5-ASA, mesalazine) is the first-line agent. Combined oral mesalazine (2.4~4.8 g/day) and rectal mesalazine (enema or suppository) has a higher remission rate than oral administration alone. 5-ASA preparations are used for both remission induction and long-term maintenance treatment, and a colorectal cancer prevention effect has also been reported.
Systemic steroids (prednisolone 40~60 mg/day orally or hydrocortisone 300 mg/day intravenously) are used for induction of acute remission. Steroids are not used for maintenance treatment and are tapered over 4~8 weeks. In steroid dependence or resistance, an immunosuppressant (azathioprine 2~2.5 mg/kg/day, 6-mercaptopurine) is added or treatment is switched early to a biologic.
In steroid-refractory disease or when immunosuppressants are ineffective, anti-TNF agents (infliximab, adalimumab, golimumab) are chosen as the first-line biologic. Vedolizumab (an anti-α4β7 integrin antibody) has fewer systemic immunosuppressive adverse effects owing to its gut-selective action and is used for remission induction and maintenance in moderate-to-severe UC. Ustekinumab (an anti-IL-12/23 antibody) is an alternative in patients refractory to anti-TNF. JAK inhibitors (tofacitinib, upadacitinib, filgotinib) are used in severe UC and when biologics are ineffective, and caution is needed regarding the risk of thrombosis and malignancy. In 2024~25, mirikizumab (anti-IL-23p19) was additionally approved for UC.
Patients who are severe by the Truelove-Witts criteria (bloody diarrhea >6 times/day + at least one of fever/tachycardia/anemia/elevated ESR) are hospitalized and given intravenous steroids (hydrocortisone 300~400 mg/day or methylprednisolone 60 mg/day). If the response is poor within 3 days, rescue treatment is given with infliximab (5 mg/kg intravenously) or cyclosporine (2~4 mg/kg/day intravenously). When toxic megacolon occurs, immediate surgical evaluation is needed.
Surgery is needed in cases refractory to drug treatment, when colorectal cancer or high-grade dysplasia develops, and in toxic megacolon, colonic perforation, and uncontrolled bleeding. The standard operation is proctocolectomy, and ileal pouch-anal anastomosis (IPAA, J-pouch surgery) is preferred as a function-preserving procedure.
Ulcerative pancolitis is the most severe of the UC phenotypes, with high frequency of relapse, surgery rate, and colorectal cancer risk.
The natural course of UC is repeated remission and relapse. Patients with pancolitis have a higher relapse rate than those with left-sided colitis or proctitis, and steroid and immunosuppressant dependence is more common. In cohort studies before the introduction of biologics, the 10-year cumulative surgery rate in pancolitis patients was reported at about 20~30%, and even in the biologic era the surgery rate is about 10~15%. Because relapse, hospitalization, and surgery rates are markedly lower in patients who achieve mucosal healing, mucosal healing is the current treatment goal.
The risk of colorectal cancer begins to rise 8~10 years after diagnosis of pancolitis. In pancolitis patients with more than 20 years of disease, the cumulative CRC risk is reported to be about 5~15%. Long-term mesalazine use, regular surveillance endoscopy, and active management of extraintestinal symptoms such as uveitis contribute to improved prognosis. In pancolitis with PSC, the risk of CRC and cholangiocarcinoma is still higher, and intensive monitoring is needed.
Pancolitis greatly reduces quality of life through symptoms such as chronic diarrhea, bloody stool, abdominal pain, and urgency. When remission is maintained and mucosal healing is achieved, quality-of-life indicators (IBDQ score, etc.) improve markedly. Psychiatric complications such as depression and anxiety are also common, and integrated management is needed.
Primary prevention of ulcerative pancolitis itself is not possible, but prevention of relapse and prevention of complications (colorectal cancer) are the core of clinical management.
After remission is achieved, mesalazine maintenance treatment (2.4 g/day or more) meaningfully lowers the relapse rate. When remission has been induced with an immunosuppressant (azathioprine) or a biologic, the relapse risk is high if remission maintenance treatment is stopped, so long-term maintenance is the rule. Regular outpatient follow-up (at 3~6-month intervals) and calprotectin monitoring are useful for early detection of asymptomatic relapse. Observational study evidence suggests that stress management, regular sleep, and a balanced diet (low-residue or Mediterranean diet) help prevent relapse.
Observational studies show that long-term use of mesalazine reduces colorectal cancer risk by 40~50%. Early detection of dysplasia through regular surveillance colonoscopy, with endoscopic resection or surgical treatment, is the key to colorectal cancer prevention. There is also some evidence that folate supplementation is associated with reduced colorectal cancer risk. In pancolitis with PSC, surveillance endoscopy is performed annually.
Patients with pancolitis receiving immunosuppressive treatment are vulnerable to infection, so pneumococcal (PCV13, PPSV23), influenza (annually), hepatitis B, herpes zoster, and HPV vaccines are given according to the recommended schedule before treatment starts. Live vaccines are contraindicated during immunosuppressant or biologic therapy.